This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
by Zacks Equity Research
J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.
Novartis (NVS) Receives EC Nod for Tasigna Label Expansion
by Zacks Equity Research
Novartis (NVS) oncology portfolio gets a boost with EC's approval for the label expansion of Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.
Theravance Shares Rise on Approval of Glaxo's COPD Therapy
by Zacks Equity Research
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
by Zacks Equity Research
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA
by Zacks Equity Research
AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.
Glaxo's Subcutaneous Formulation of Benlysta Approved in EU
by Zacks Equity Research
GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.
Mylan (MYL) Misses on Earnings and Sales Estimates in Q3
by Zacks Equity Research
Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.
Emergent (EBS) Q3 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Emergent's (EBS) earnings and revenues beat estimates in Q3. Revenues also rise year over year on higher product sales and increase in contract manufacturing revenues.
Novartis Buys French Radiopharmaceutical Company
by Zacks Equity Research
Novartis (NVS) plans to acquire France-based Advanced Accelerator Applications. The takeover will add RadioLigand Therapy, Lutathera, in its portfolio with potential to drive growth in the near term.
Foreign Stock Roundup: Novartis, Bayer, Glaxo, Total Beat on Earnings
by Swarup Gupta
Political developments guided the movement of most non U.S. markets this week.
Glaxo (GSK) Q3 Earnings Beat, Revenues In Line, Shares Down
by Zacks Equity Research
Glaxo's (GSK) Q3 earnings top estimates while revenues match the same. However, the bottom was flat at constant exchange rates (CER).
Glaxo (GSK) Q3 Earnings Surpass Estimates, Revenues In Line
by Zacks Equity Research
Glaxo's (GSK) Q3 earnings beat estimates, with revenues in line. Glaxo maintained its core 2017 earnings growth, with no Advair generics expected to be launched this year.
Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.
Should You Buy GlaxoSmithKline (GSK) Ahead of Earnings?
by Zacks Equity Research
GlaxoSmithKline (GSK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is Celgene (CELG) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.
Is Gilead (GILD) Poised for a Beat This Earnings Season?
by Zacks Equity Research
A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.
Foreign Stock Roundup SAP, Taiwan Semiconductor Earnings Impress, Ericsson Disappoints
by Swarup Gupta
Heightened geopolitical concerns, emanating from the Catalonia crisis and stalled Brexit negotiations weighed on Europe's stocks last week.
Novartis Reports Positive Results on Thrombocytopenia Drug
by Zacks Equity Research
Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.
FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx
by Zacks Equity Research
Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.
Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
by Zacks Equity Research
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit
by Zacks Equity Research
Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.
Emergent Completes Acquisition of Anthrax Drug Raxibacumab
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.
Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg
by Zacks Equity Research
Mylan N.V. (MYL) gets a boost with the FDA's approval of the generic version of multiple sclerosis drug Copaxone.
Advanced Accelerator (AAAP) Cancer Therapy Approved in EU
by Zacks Equity Research
Advanced Accelerator Applications' (AAAP) Lutathera gets approval in Europe as its first radionuclide therapy for the treatment of tumors in the gut.
Agenus (AGEN) Remains Focused on Drug Development Programs
by Zacks Equity Research
Agenus' (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.